mProX™ Human NR3C2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Nuclear Receptor
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Cynthia
Verified Customer
Robert
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 NR3C2 inhibits proliferation, colony formation, invasiveness and epithelial-tomesenchymal transition.
Overexpression of NR3C2 inhibits Panc-1 and MiaPaCa-2 cell growth. Comparing NR3C2-overexpressing cells to control cells, fewer colonies were formed.
Ref: Yang, Shouhui, et al. "A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2." Cancer research 76.13 (2016): 3838-3850.
Pubmed: 27197190
DOI: 10.1158/0008-5472.CAN-15-2841
Research Highlights
Despite the fact that HPA-axis reactivity has been frequently linked to cognitive functioning, it is unclear whether this relationship is positive or negative. Therefore, genetic factors that affect both cognitive functioning and HPA-axis reactivity may help explain the relationship between stress and cognition.
Plieger, Thomas, et al. "The role of genetic variation in the glucocorticoid receptor (NR3C1) and mineralocorticoid receptor (NR3C2) in the association between cortisol response and cognition under acute stress." Psychoneuroendocrinology 87 (2018): 173-180.
Pubmed:
29100174
DOI:
10.1016/j.psyneuen.2017.10.020
The GA haplotype in NR3C2 and the mutation rs2070951 were linked to a higher incidence of cCSC in this investigation. The pathophysiology of cCSC may involve the mineralocorticoid receptor, according to the findings of this genetic investigation.
van Dijk, Elon HC, et al. "Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy." JAMA ophthalmology 135.5 (2017): 446-451.
Pubmed:
28334414
DOI:
10.1001/jamaophthalmol.2017.0245